vTv Therapeutics' (VTVT) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• vTv Therapeutics' stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating continued negative sentiment towards the company's stock.
• Despite the bearish outlook, HC Wainwright has a "buy" rating on vTv Therapeutics with a price target of $36.00, contrasting with the consensus rating of "Hold" from multiple analysts.
• In its latest earnings report, vTv Therapeutics missed EPS estimates, reporting ($0.92), which was lower than the expected ($0.85).

vTv Therapeutics (NASDAQ:VTVT - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, August 13th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, vTv Therapeutics has a consensus rating of "Hold" and a consensus target price of $35.50.

vTv Therapeutics Stock Down 2.2%

Shares of VTVT stock traded down $0.49 during mid-day trading on Tuesday, reaching $21.38. The stock had a trading volume of 1,714 shares, compared to its average volume of 6,077. The firm's 50 day simple moving average is $18.94 and its 200 day simple moving average is $18.06. vTv Therapeutics has a one year low of $12.62 and a one year high of $26.99. The firm has a market cap of $84.22 million, a PE ratio of -6.85 and a beta of 0.67.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.07).

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. Connective Capital Management LLC purchased a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,377 shares of the biotechnology company's stock, valued at approximately $162,000. Connective Capital Management LLC owned approximately 0.29% of vTv Therapeutics at the end of the most recent reporting period. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.